Episode 127
The FDA on Molnupiravir and COVID-19: What physicians need to know, Part III
In part three of this three-part series, Aimee Hodowanec, MD, senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs, FDA, discusses what physicians need to know about Molnupiravir as treatment for COVID-19.
February 18, 202212m 33s
Audio is streamed directly from the publisher (pdst.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In part three of this three-part series, Aimee Hodowanec, MD, senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs, FDA, discusses what physicians need to know about Molnupiravir as treatment for COVID-19.
Topics
molnupiravirhodowanecaimeefdatherapeuticspart 3covid 19division of antiviralspart iii